BR112018009463A2 - ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia - Google Patents

ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia

Info

Publication number
BR112018009463A2
BR112018009463A2 BR112018009463A BR112018009463A BR112018009463A2 BR 112018009463 A2 BR112018009463 A2 BR 112018009463A2 BR 112018009463 A BR112018009463 A BR 112018009463A BR 112018009463 A BR112018009463 A BR 112018009463A BR 112018009463 A2 BR112018009463 A2 BR 112018009463A2
Authority
BR
Brazil
Prior art keywords
trials
methods
selecting
treatment regimen
cpx
Prior art date
Application number
BR112018009463A
Other languages
English (en)
Other versions
BR112018009463A8 (pt
Inventor
Tyner Jeffrey
Mayer Lawrence
Gordon Max
Tardi Paul
Original Assignee
Celator Pharmaceuticals Inc
Univ Oregon Health & Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celator Pharmaceuticals Inc, Univ Oregon Health & Science filed Critical Celator Pharmaceuticals Inc
Publication of BR112018009463A2 publication Critical patent/BR112018009463A2/pt
Publication of BR112018009463A8 publication Critical patent/BR112018009463A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

a presente invenção refere-se a métodos diagnósticos para identificar sujeitos que possuem câncer apropriados para o tratamento com cpx 351 que incluem testes genéticos e ex vivo de células de um sujeito candidato. o tratamento de combinação com inibidores de flt 3 e cpx 351 melhora a toxicidade e absorção de cpx 351.
BR112018009463A 2015-11-11 2016-11-10 ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia BR112018009463A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562254109P 2015-11-11 2015-11-11
PCT/US2016/061444 WO2017083592A1 (en) 2015-11-11 2016-11-10 Assays and methods for selecting a treatment regimen for a subject with leukemia

Publications (2)

Publication Number Publication Date
BR112018009463A2 true BR112018009463A2 (pt) 2018-11-06
BR112018009463A8 BR112018009463A8 (pt) 2019-02-26

Family

ID=58695625

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018009463A BR112018009463A8 (pt) 2015-11-11 2016-11-10 ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia

Country Status (15)

Country Link
US (3) US10927418B2 (pt)
EP (1) EP3373919A4 (pt)
JP (2) JP6976941B2 (pt)
KR (1) KR20180108572A (pt)
CN (2) CN108778260A (pt)
AU (2) AU2016353163B2 (pt)
BR (1) BR112018009463A8 (pt)
CA (2) CA3005076C (pt)
CO (1) CO2018005846A2 (pt)
HK (1) HK1258724A1 (pt)
IL (2) IL292080A (pt)
MX (1) MX2018005771A (pt)
MY (1) MY193531A (pt)
SG (2) SG11201804020YA (pt)
WO (1) WO2017083592A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3005076C (en) * 2015-11-11 2024-01-02 Celator Pharmaceuticals, Inc. Assays and methods for selecting a treatment regimen for a subject with leukemia
CA3114002A1 (en) * 2018-09-25 2020-04-02 Celator Pharmaceuticals, Inc. Low-intensity treatment of hematological disorders
WO2020102595A1 (en) * 2018-11-14 2020-05-22 Dana-Farber Cancer Institute, Inc. Determining treatment response in single cells
CN111870600B (zh) * 2020-07-13 2022-04-15 中南大学湘雅二医院 索拉非尼、瑞戈非尼及其类似物或衍生物的新应用
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2407169A1 (en) 2004-04-22 2012-01-18 Celator Pharmaceuticals, Inc. Combination formulations of anthracycline agents and cytidine analogs
PL2120568T3 (pl) 2007-02-16 2018-03-30 Celator Pharmaceuticals, Inc. Stały stosunek leków w leczeniu krwiotwórczych nowotworów i chorób proliferacyjnych
TW200901975A (en) 2007-03-05 2009-01-16 Kyowa Hakko Kogyo Kk Pharmaceutical composition
TWI546537B (zh) * 2009-05-19 2016-08-21 維維亞生技公司 提供針對血液腫瘤之體外個人化藥物測試之方法
US20120010229A1 (en) * 2010-07-08 2012-01-12 Macdougall John R Therapeutic regimens for hedgehog-associated cancers
JP6133308B2 (ja) * 2011-10-21 2017-05-24 セレーター ファーマシューティカルズ インコーポレイテッド 凍結乾燥リポソーム
WO2014087018A1 (en) * 2012-12-07 2014-06-12 Evotec (München) Gmbh Markers for responsiveness to an inhibitor of flt3
EP3191126B1 (en) * 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
CA3005076C (en) * 2015-11-11 2024-01-02 Celator Pharmaceuticals, Inc. Assays and methods for selecting a treatment regimen for a subject with leukemia
CA3114002A1 (en) * 2018-09-25 2020-04-02 Celator Pharmaceuticals, Inc. Low-intensity treatment of hematological disorders

Also Published As

Publication number Publication date
US20230279503A1 (en) 2023-09-07
AU2022291559A1 (en) 2023-02-02
US20210246512A1 (en) 2021-08-12
KR20180108572A (ko) 2018-10-04
US10927418B2 (en) 2021-02-23
US20180327854A1 (en) 2018-11-15
JP6976941B2 (ja) 2021-12-08
CN115414376A (zh) 2022-12-02
CA3005076C (en) 2024-01-02
HK1258724A1 (zh) 2019-11-15
AU2016353163A1 (en) 2018-06-07
EP3373919A4 (en) 2019-06-19
MX2018005771A (es) 2019-03-14
AU2016353163B2 (en) 2022-09-29
CN108778260A (zh) 2018-11-09
US11746386B2 (en) 2023-09-05
IL259271B (en) 2022-05-01
SG10202112699UA (en) 2021-12-30
SG11201804020YA (en) 2018-06-28
CA3219061A1 (en) 2017-05-18
CO2018005846A2 (es) 2018-08-21
WO2017083592A1 (en) 2017-05-18
EP3373919A1 (en) 2018-09-19
CA3005076A1 (en) 2017-05-18
JP2018535975A (ja) 2018-12-06
BR112018009463A8 (pt) 2019-02-26
IL292080A (en) 2022-06-01
JP2022024031A (ja) 2022-02-08
RU2018121249A3 (pt) 2020-03-17
IL259271A (en) 2018-07-31
MY193531A (en) 2022-10-18
RU2018121249A (ru) 2019-12-17

Similar Documents

Publication Publication Date Title
BR112018009463A2 (pt) ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia
BR112017012222A2 (pt) métodos para derivar um biomarcador de assinatura gênica e para tratar um paciente que tem um tumor, método e sistema para testar uma amostra de tumor removida de um paciente, e, kit.
CO2019004630A2 (es) Composiciones de células t con car anti-bcma
UY37155A (es) Inhibidores de ret
CL2017003069A1 (es) Métodos para diagnosticar y tratar el cáncer.
BR112016017256A2 (pt) combinação de um antagonista de pd-1 e um inibidor de vegfr para o tratamento de câncer
NI201700035A (es) Uso de paneles de genes mutantes del fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor del fgfr
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
BR112017027954A2 (pt) métodos de tratamento de tumores de célula epitelioide
EP3839510A3 (en) Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
MX2019007653A (es) Métodos para la optimización de ensayos rápidos de susceptibilidad antimicrobiana.
UY37113A (es) Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento
AR105618A1 (es) Metilación del promotor del ligando al receptor de muerte programada (pd-l1) en cáncer
WO2015073896A3 (en) Biomarkers for psma targeted therapy for prostate cancer
BR112017015627A2 (pt) Compostos de piperidina ureia substituída com 4- metilsulfonila para o tratamento de cardiomiopatia dilatada (dcm)
CL2019002438A1 (es) Uso de biomarcadores en la identificación de pacientes con cáncer que serán sensibles al tratamiento con un inhibidor de prmt5.
MX2016012285A (es) Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
BR112017006531A2 (pt) composições, kits e métodos para induzir citorresistência adquirida utilizando indutores de proteínas de estresse
BR112014032892A2 (pt) processo de amplificação por rcp e de detecção de pelo menos uma sequência-alvo nucleotídica, dispositivo de amplificação e de detecção rápida de pelo menos uma sequência-alvo nucleotídica e estojo de amplificação por rcp e de detecção de pelo menos uma sequência nucleotídica-alvo
BR112015009438A2 (pt) uso de um anticorpo que se liga à ly75, método de detecção, diagnóstico e/ou avaliação ou monitoramento da progressão de um câncer e método para identificação de um agente para o tratamento ou profilaxia de um câncer
ES2811835T3 (es) Procedimiento para determinar el riesgo de toxicidad por 5-fluorouracilo
BR112017019841A2 (pt) técnica de análise de amostra de tecido
ECSP18091065A (es) Ésteres de oxaborol y sus usos
CO2019002608A2 (es) Biomarcadores de arn para angioedema hereditario

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]